Business Wire

Toshiba’s New Simulation Technology for Model-Based Development Shortens Verification Times for Automotive Semiconductors by About 90 Percent

21.9.2021 07:50:00 EEST | Business Wire | Press release

Share

Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has developed a model-based development (MBD) simulation technology that shortens verification times for automotive semiconductors by about 90 percent.[1] The technology allows automotive equipment developers to quickly evaluate designs using Toshiba’s automotive semiconductors, helping to shorten development times.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005989/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Simulation results with the new technology (Graphic: Business Wire)

As electric vehicles grow in popularity and advanced driver-assistance systems become standard, automotive equipment is growing increasingly advanced and complicated. Model-based development, a development methodology that uses software to simulate models and evaluate performance in real-time, is helping product developers to refine complex design processes. In the automobile industry, MBD contributes to development advances by simultaneously progressing design and verification prior to making prototypes.

MBD separates functions into blocks and verifies total vehicle behavior by connecting each block. Detailed simulation models that include the behavior of semiconductors in individual blocks are required to verify heat and electromagnetic interference (EMI), essential parameters for assessing the performance of automotive equipment. However, as models become more detailed and precise, verification times are growing longer.

Toshiba took a long hard look at its current evaluation and verification technology for automotive equipment. Sub-systems like electric power steering comprise semiconductor-based electronic circuits that work in microseconds along with mechanical components, gears and shafts, that work in milliseconds. Toshiba’s current technology simulates the electronic circuits and mechanical components at the same time, on a microsecond basis, but this results in a large number of unnecessary and time-consuming calculations in the mechanical components. The technology is also complicated because it adopts the SPICE model—Simulation Program with Integrated Circuit Emphasis—that defines over 100 parameters for the simulation of semiconductor behavior.

Toshiba’s new modeling technology, “Accu-ROMTM”, separately calculates the electronic circuits and the mechanical components. First it verifies the mechanical components, then simplifies the model for mechanical components and finally verifies the total system, including its electric circuits. This approach eliminates unnecessary calculations. In evaluating the electric circuits, the model automatically generates a Very High speed integrated circuit Hardware Description Language-Analog Mixed Signal (VHDL-AMS) model from the SPICE model. VHDL-AMS model allows the verification range to be limited to essential parameters, such as heat and EMI noise, shortening the verification time. For example, verification of a power steering system with Toshiba’s current technology takes 32 hours 51 minutes, but that falls to 3 hours 27 minutes[1] with the new technology.

Toshiba will use the new technology to promote development of high-heat dissipation and low noise automotive semiconductors, and to provide its customers with a development environment which makes it easier to use Toshiba’s products. In addition to automotive applications, Toshiba will use the new technology in semiconductors for other applications, such as industrial equipment and home appliances.

Notes
[1] Verification times for simulation of three-phase inverter circuits in an automotive electric power steering system during a right turn with a duration of six seconds.

* Accu-ROM™ is a trademark of Toshiba Electronic Device & Storage Corporation.
* All other company names, product names and service names may be trademarks of their respective companies.

About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation, a leading supplier of advanced semiconductor and storage solutions, draws on over half a century of experience and innovation to offer customers and business partners outstanding discrete semiconductors, system LSIs and HDD products.
The company's 22,000 employees around the world share a determination to maximize product value, and promote close collaboration with customers in the co-creation of value and new markets. With annual sales now surpassing 710-billion yen (US$6.5 billion), Toshiba Electronic Devices & Storage Corporation looks forward to building and to contributing to a better future for people everywhere.
Find out more at https://toshiba.semicon-storage.com/ap-en/top.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Motohiro Ajioka
Corporate Communications & Market Intelligence Group
Business Planning Div.
Toshiba Electronic Devices & Storage Corporation
semicon-NR-mailbox@ml.toshiba.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye